OPKO’s ModeX Starts Phase 1 Trial for Broad-Spectrum COVID-19 Antibody
Event summary
- ModeX Therapeutics, an OPKO Health subsidiary, dosed first participants in a Phase 1 trial for MDX2301, a tetravalent bispecific antibody designed to neutralize all known SARS-CoV-2 variants.
- The randomized, double-blind, placebo-controlled study will enroll 80 participants and evaluate safety, tolerability, and pharmacokinetics across intravenous, intramuscular, and subcutaneous administration routes.
- MDX2301 is funded by a $56 million contract from the U.S. Department of Health and Human Services (HHS) via BARDA.
The big picture
OPKO Health is betting on ModeX Therapeutics’ multispecific antibody technology to address the ongoing challenge of SARS-CoV-2 evolution. The Phase 1 trial of MDX2301 comes amid persistent public health risks for vulnerable populations, including the elderly and immunocompromised individuals. If successful, this approach could redefine preventive strategies for infectious diseases by combining multiple binding domains in a single molecule.
What we're watching
- Clinical Efficacy
- Whether MDX2301’s tetravalent design can deliver broader and more durable protection against emerging SARS-CoV-2 variants compared to conventional monoclonal antibodies.
- Regulatory Pathway
- The pace at which ModeX can advance MDX2301 through Phase 1, given the evolving landscape of COVID-19 prevention and treatment.
- Platform Potential
- How ModeX’s multispecific antibody platform could be leveraged for other infectious diseases beyond COVID-19, such as influenza or emerging viral threats.